You can Subscribe to our RSS FEED:
which delivers brain tumor news and additions
to the website via RSS.
Click HERE for details on RSS.
Displaying items 1 to 25 of about 5510
CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
Our webinar with Dr Linda Liau on DcVax is tonight 12/5/22 at 8:30pm Eastern
Musella Foundation Brain Tumor Copay Program now open for new and renewal applications!
Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation
Convection-enhanced delivery of topotecan active in glioblastoma
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registry
Ulixertinib may change childhood brain tumor treatment
The accelerated approval pathway is evolving in plain sight, with or without congressional help
Musella Foundation 2022 Highlights
. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
The children`s brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science
DCVAX webinar: Tuesday Nov 29, 2022 at 7pm Eastern
- Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
POSITIVE UPDATED INTERIM RESULTS FROM
NOX-A12 GLORIA PHASE 1/2 IN BRAIN CANCER PRESENTED
AT THE SOCIETY FOR NEURO-ONCOLOGY 2022 ANNUAL MEETING
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
Association of Autologous Tumor Lysate Loaded Dendritic Cell Vaccination With Extended Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Vaccine shown to prolong life of patients with aggressive brain cancer
xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL
Starving Cancer Cells Without Starving You
First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma
Giving Tuesday Contest
Brain Tumor News Blast
Click HERE to subscribe!
Copyright © 1993 - 2022 Musella Foundation- All Rights Reserved.
Website by LcsProductionDesign.com